PPI Platform Programs

About Molecure

Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.

Therapeutic Areas